We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA, EMA Collaboration May Speed US Progress on Biosimilars Review
FDA, EMA Collaboration May Speed US Progress on Biosimilars Review
June 24, 2011
CHICAGO — The FDA and European Medicines Agency (EMA) have agreed to work together toward harmonizing biosimilars regulations, which may help the FDA catch up in its development of an abbreviated pathway to approve the generic biologics.